Tetra Radar · FDA Approvals · Decision date

UX111: FDA decision date

Ultragenyx Pharmaceutical Inc (RARE) · 19 September 2026

The FDA granted the BLA Priority Review and assigned a PDUFA action date of September 19, 2026.

Source: 10-Q of 5 August 2026

The FDA approved it on 17 September 2026.

The FDA approved Fayuvi for the treatment of neurologic manifestations of mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo Syndrome type A) in pediatric patients with preserved neurodevelopmental function.

Ultragenyx Pharmaceutical Inc on Tetra Radar

A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.

Get the Dispatch free.